Trial Profile
Exploratory study for SGLT2 inhibitor -Glucose lowering action, influences of dietary habits/exercise habits on therapeutic effects, and treatment satisfaction
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Oct 2018
Price :
$35
*
At a glance
- Drugs Canagliflozin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms Canak
- 01 Oct 2018 Status changed from active, no longer recruiting to completed.
- 23 May 2017 Status changed from recruiting to active, no longer recruiting.
- 10 Nov 2015 Status changed from not yet recruiting to recruiting as reported by University Hospital Medical Information Network - Japan record.